Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

276 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antiretroviral Boosting Agent Cobicistat Increases the Pharmacokinetic Exposure and Anticoagulant Effect of Dabigatran in HIV-Negative Healthy Volunteers.
Gordon LA, Kumar P, Brooks KM, Kellogg A, McManus M, Alfaro RM, Nghiem K, George JM, Lozier J, Penzak SR, Hadigan C. Gordon LA, et al. Among authors: george jm. Circulation. 2016 Dec 6;134(23):1909-1911. doi: 10.1161/CIRCULATIONAHA.116.025257. Circulation. 2016. PMID: 27920076 Free PMC article. Clinical Trial. No abstract available.
Decreased Absorption of Dolutegravir and Tenofovir Disoproxil Fumarate, But Not Emtricitabine, in an HIV-Infected Patient Following Oral and Jejunostomy-Tube Administration.
Brooks KM, Garrett KL, Kuriakose SS, George JM, Balba G, Bailey B, Anderson M, Lane HC, Maldarelli F, Pau AK. Brooks KM, et al. Among authors: george jm. Pharmacotherapy. 2017 Aug;37(8):e82-e89. doi: 10.1002/phar.1960. Epub 2017 Jul 18. Pharmacotherapy. 2017. PMID: 28556353 Free PMC article.
Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran.
Kumar P, Gordon LA, Brooks KM, George JM, Kellogg A, McManus M, Alfaro RM, Nghiem K, Lozier J, Hadigan C, Penzak SR. Kumar P, et al. Among authors: george jm. Antimicrob Agents Chemother. 2017 Oct 24;61(11):e01201-17. doi: 10.1128/AAC.01201-17. Print 2017 Nov. Antimicrob Agents Chemother. 2017. PMID: 28848011 Free PMC article. Clinical Trial.
Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine.
Brooks KM, George JM, Pau AK, Rupert A, Mehaffy C, De P, Dobos KM, Kellogg A, McLaughlin M, McManus M, Alfaro RM, Hadigan C, Kovacs JA, Kumar P. Brooks KM, et al. Among authors: george jm. Clin Infect Dis. 2018 Jul 2;67(2):193-201. doi: 10.1093/cid/ciy082. Clin Infect Dis. 2018. PMID: 29415190 Free PMC article. Clinical Trial.
Quantitative Benefit-Risk Assessment of P-gp-Mediated Drug-Drug Interactions of Dabigatran Coadministered With Pharmacokinetic Enhancers in Patients With Renal Impairment.
Lingineni K, Farhan N, Kim S, Cristofoletti R, Gordon LA, Kumar P, Penzak S, Hadigan C, George JM, Brown JD, Schmidt S. Lingineni K, et al. Among authors: george jm. Clin Pharmacol Ther. 2021 Jan;109(1):193-200. doi: 10.1002/cpt.2087. Epub 2020 Dec 10. Clin Pharmacol Ther. 2021. PMID: 33073366
Antiretroviral therapy: current drugs.
Pau AK, George JM. Pau AK, et al. Among authors: george jm. Infect Dis Clin North Am. 2014 Sep;28(3):371-402. doi: 10.1016/j.idc.2014.06.001. Infect Dis Clin North Am. 2014. PMID: 25151562 Free PMC article. Review.
276 results